PWPhilip J. Wiffen

Philip J. Wiffen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philip J. Wiffen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • R Andrew Moore

    University of Oxford Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics) Pain Research UnitChurchill Hospital Oxford UK OX3 7LE

    14 shared publications
  • Sheena Derry

    University of Oxford Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics) Pain Research UnitChurchill Hospital Oxford UK OX3 7LE

    14 shared publications
  • Bee Wee

    Churchill Hospital Nuffield Department of Medicine and Sir Michael Sobell House Old RoadHeadington Oxford UK OX3 7LJ

    5 shared publications
  • Daniel B Carr

    Pain Research, Education and Policy (PREP) Program, Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA

    2 shared publications
  • Dominic Aldington

    Royal Hampshire County Hospital; Winchester UK SO22 5DG

    2 shared publications
  • Eija A Kalso

    Helsinki University and Helsinki University Hospital Department of Anaesthesia, Intensive Care and Pain Medicine Helsinki Finland

    2 shared publications

Latest Publications

  • Open Access

    Guiding authors

    by Phil Wiffen


  • Crystal ball gazing

    by Phil Wiffen

    The PwC Health Research Institute1 aims to provide ‘intelligence, perspective and analysis on trends affecting health related industries’. Each year they look forward to what they consider to be the main issues to be faced in the coming year. While they are focused on issues in the USA, there are trends which we would do well to take note of. These possible trends also raise questions about the way we run our pharmacy services. The trends are helpfully described in Healthcare IT News.2 The report3 looking into 2018 highlights 12 trends and six of these are worth considering. ­ 1. ‘Meet your co-worker—Artificial intelligence (AI)’ Increasingly, AI is appearing in hospital pharmacies in the form of robotics for pack dispensing but also in cytotoxic and intravenous additive preparations. PwC predicts a trend where more tasks will be automated such as routine paperwork and scheduling. However, 75% of executives said they planned to move in this direction but … Correspondence to Professor Phil Wiffen, Pain Research Unit, Churchill Hospital, Oxford OX3 7LE, UK; phil.wiffen{at}ndcn.ox.ac.uk

  • Open Access

    Change blindness

    by Phil Wiffen

    The Ashmolean Museum in Oxford is the oldest public museum in the world and is well known for its wide range of art and artefacts. It is visited by around one million people each year. This venue became the setting for an interesting piece of research led by a team from Oxford University. Change blindness occurs when changes in images are not noticed by an observer. In other words, we do not accurately record what is in front of us. The team reported their findings in a paper1 published in 2018 and observed three main conclusions. First that change blindness occurs when similar objects are viewed briefly in both the real world and then onscreen. Second that the mean levels of change blindness are similar between … Correspondence to Professor Phil Wiffen, Pain Research Unit, Churchill Hospital, Oxford OX3 7LE, UK; phil.wiffen{at}ndcn.ox.ac.uk


  • Open Access

    An online supplemental issue forEJHP

    by Phil Wiffen

    I am very happy to present European Journal of Hospital Pharmacy ’s first online supplement focusing on clinical pharmacy activities. This issue is timed to coincide with the 2018 European Association of Hospital Pharmacists Congress and we are making all the articles free to access until the 2019 Congress. So why are we producing an online-only issue? First let me say that there is no intention … Correspondence to Professor Phil Wiffen, Pain Research Unit, Churchill Hospital, Oxford OX3 7LE, UK; phil.wiffen{at}ndcn.ox.ac.uk

  • Open Access

    Could you be a peer reviewer?

    by Phil Wiffen

    Most authors and readers of scientific papers agree that peer review is an important part of the publishing process. However, getting peer reviewers is an increasing challenge for many journals including European Journal of Hospital Pharmacy ( EJHP ). In an editorial around 4 years ago, I mentioned that we frequently contact seven or more potential reviewers in order to obtain peer review reports. Since then, things have worsened, and now it is not uncommon to approach up to 15 potential reviewers in order to obtain sufficient reports. As an editorial team, we are incredibly grateful for those who undertake peer review for us, many of whom submit high-quality reports. However, we do need more peer reviewers so this is a call to sign up! For this journal, peer review is a key stage in the consideration of a paper … Correspondence to Professor Phil Wiffen, Pain Research Unit, Churchill Hospital, Oxford OX3 7LE, UK; phil.wiffen{at}ndcn.ox.ac.uk


  • Open Access

    Apocalypse: the end of antibiotics?

    by Phil Wiffen

    Oxford dictionaries define apocalypse as ‘an event involving destruction or damage on a catastrophic scale’. In October this year, England’s chief medical officer, Sally Davies, reported that the world was facing a postantibiotic apocalypse that will lead to the end of modern medicine as we know it. I would not normally write another editorial on antibiotic resistance so soon after the call in the November 2017 issue, which reminded pharmacists of their gatekeeper role in the use of antimicrobials, but such radical comments have to be taken seriously. The 2017 English Surveillance Programme for Antimicrobial Utilisation and Resistance report1 highlights the issues facing England and also has useful information for Europe. The data make worrying reading. In 2016 the most common cause of bloodstream infections was Escherichia coli , where 41% were resistant to co-amoxiclav, the most common antibiotic used. Twenty per cent … Correspondence to Professor Phil Wiffen, Pain Research Unit, Churchill Hospital, Oxford OX3 7LE, UK; phil.wiffen{at}ndcn.ox.ac.uk


  • Open Access

    Pharmacists are the gatekeepers to the use of antimicrobials

    by Phil Wiffen

    Who says? The recent EU guidelines for the prudent use of antimicrobials 1 in human health has exactly this statement. It is rare to find such a strong endorsement of pharmacists’ roles and this presents both a challenge and an opportunity. The guidelines go on to state that pharmacists can act (or should!) as an important source of advice and information for patients and prescribers on safe, rational and effective use. This is explicitly described with nine suggestions including adherence, storage and disposal. The guideline recognises that certain things need to put into place including appropriate training to ensure the prudent use of antimicrobials and to help manage patient expectations. Could this be a helpful track in a future European Association of Hospital Pharmacists … Correspondence to Professor Phil Wiffen, Pain Research Unit, Churchill Hospital, Oxford OX3 7LE, UK; phil.wiffen{at}ndcn.ox.ac.uk